Myogenic differentiation is accompanied by alterations in the chromatin states, which permit or restrict the transcriptional machinery and thus impact distinctive gene expression profiles. The mechanisms by which higher-order chromatin remodeling is associated with gene activation and silencing during differentiation is not fully understood. In this study, we provide evidence that the euchromatic lysine methyltransferase GLP regulates heterochromatin organization and myogenic differentiation. Interestingly, GLP represses expression of the methyl-binding protein MeCP2 that induces heterochromatin clustering during differentiation. Consequently, MeCP2 and HP1γ localization at major satellites are altered upon modulation of GLP expression. In GLP knockdown cells, depletion of MeCP2 restored both chromatin organization and myogenic differentiation. These results identify a novel regulatory axis between a histone methylation writer and DNA methylation reader, which is important for heterochromatin organization during differentiation.
Introduction
Myogenic differentiation is accompanied by spatial reorganization of chromatin. In addition to epigenetic modifications that occur locally at promoters, heterochromatin is modified and gets progressively clustered in distinctive chromocenters. Concomitantly, major and minor satellite RNA transcripts accumulate during differentiation (Brero et al., 2005; Terranova et al., 2005; Agarwal et al., 2007; Luo et al., 2009; Sdek et al., 2011; Chen et al., 2017) DNA methylation at CpG dinucleotides and histone 3 lysine 9 methylation (H3K9me) are hallmarks of heterochromatin. Consequently, proteins that recognize methylation marks, such as methyl-CpG-binding domain (MBD) protein MeCP2, as well as heterochromatin protein 1 (HP1), are enriched in pericentric heterochromatin. Moreover, MeCP2 and HP1 result in heterochromatin clustering, which is thought to be essential for maintenance of the differentiated state in skeletal and cardiac myocytes (Brero et al., 2005; Agarwal et al., 2007; Sdek et al., 2011) . The interplay between DNA and histone modifications in heterochromatin organization is complex and not fully understood. For instance, the absence of DNA methylation in DNMT1 or DNMT3a/3b deficient cells results in reduced MeCP2 localization but does not alter Suv39h-mediated H3K9 tri-methylation (H3K9me3) marks or HP1α localization at pericentric heterochromatin (Lehnertz et al., 2003) . Furthermore, while MeCP2 interacts with Suv39h1/h2 (Fuks et al., 2003b) , exogenous MeCP2 still induces pericentric heterochromatin clustering in Suv39h double-null cells, indicating that the MeCP2-Suv39h interaction is not essential (Brero et al., 2005) . On the other hand, H3K9me is required for DNA methylation (Lehnertz et al., 2003) . DNMT3a and 3b are directed to H3K9me marks via association with HP1α and HP1β (Fuks et al., 2003a) . In Suv39h null cells, DNA methylation and MeCP2 localization is reduced at pericentric satellite repeats (Lehnertz et al., 2003) .
G9a and G9a-like protein (GLP) are the primary mediators of H3K9me2 in euchromatin (Tachibana et al., 2005; Trojer and Reinberg, 2007) and their auto-methylation acts as a docking site for HP1α and HP1γ (Chin et al., 2007; Fritsch et al., 2010) . Depletion of GLP or G9a restricts localization of HP1γ to heterochromatin in mouse embryonic stem cells (Tachibana et al., 2005) . In addition, G9a/GLP also associate with DNMT3a via MPP8 (Chang et al., 2011) . Gene disruption studies in mice have shown that loss of G9a or GLP abrogates global H3K9me2 and results in embryonic lethality at E9.5 (Tachibana et al., 2005) . Notably, the Ankyrin (ANK) repeats of GLP are required for efficient establishment and maintenance of H3K9me2 during embryonic development while the ANK repeats of G9a are dispensable (Liu et al., 2015) , indicating independent functions of GLP and G9a during embryonic development. A few recent studies have suggested that GLP may be involved in skeletal myogenesis. For instance, GLP stabilizes PRDM16 and steers Myf5 + precursor cells towards a brown adipocyte lineage, in turn suppressing myogenic promoters (Ohno et al., 2013) . In addition, conditional deletion of GLP in neurons results in the upregulation of myogenic genes (Schaefer et al., 2009) . In cultured myoblasts, GLP overexpression was found to block myogenic differentiation (Battisti et al., 2016) . However, the molecular mechanisms by which GLP inhibits muscle differentiation and its potential role in heterochromatin organization is not well understood.
In this study, we have examined the role of GLP in skeletal myogenesis. We show that GLP overexpression inhibits terminal differentiation of muscle precursor cells. The defect in myogenic differentiation correlates with impaired heterochromatin clustering. HP1γ localization at heterochromatin and its occupancy at major satellites is reduced in GLP-overexpressing cells, and conversely is increased in GLP knockdown primary myoblasts. These changes occur in the absence of any changes in H3K9me3 levels or in DNA methylation. Interestingly however, MeCP2, which recruits HP1γ to heterochromatin, is repressed in GLP-overexpressing cells resulting in reduced occupancy at major satellites. We demonstrate that MeCP2 is a direct GLP target gene. Consequently, depletion of endogenous MeCP2 expression in the background of GLP knockdown reverts the enhanced myogenic differentiation and HP1γ localization to chromocenters seen in GLP knockdown cells. Taken together, our results provide evidence that GLP influences chromatin states and myogenic differentiation through repression of MeCP2.
Results

GLP inhibits skeletal muscle differentiation
While recent studies have implicated GLP in skeletal muscle differentiation (Schaefer et al., 2009; Ohno et al., 2013; Battisti et al., 2016) , the underlying mechanisms are not completely understood. To this end, we first examined endogenous GLP mRNA and protein expression in C2C12 cells. Similar to G9a (Ling et al., 2012; Jung et al., 2015; Ow et al., 2016) , GLP expression declined during differentiation and inversely correlated with differentiation markers Myogenin and TroponinT ( Figure 1A and B). To test its potential role in myogensis, we performed loss-of-function studies and examined proliferation and differentiation of GLP knockdown cells. C2C12 cells were transfected with scrambled siRNA (Control) or GLP-specific siRNA (siGLP) for 48 h ( Figure 1C ). Cells were pulsed with BrdU and stained with anti-BrdU antibody. No significant changes in proliferation of siGLP cells were observed compared to control cells ( Figure 1D ). Interestingly however, siGLP cells exhibited a significant increase in myogenic differentiation as seen by immunofluorescence staining using anti-myosin heavy chain (MHC) antibody and myogenic index ( Figure 1E) . Consistently, Myogenin, TroponinT, and MyoD expression levels were elevated in siGLP cells upon differentiation, while G9a levels were not overtly altered ( Figure 1F) . To validate the impact of GLP on differentiation, siRNA-mediated depletion of GLP in mouse primary myoblasts was performed ( Figure 1G ). Similar to the effect in C2C12 cells, siGLP primary myoblasts expressed increased levels of Myogenin and myosin heavy chain 1 (Myh1) during differentiation ( Figure 1G ). Taken together, these results indicate that endogenous GLP inhibits myogenesis.
The SET domain and ANK repeats of GLP are required to inhibit myogenic differentiation
We next examined whether overexpression of GLP is sufficient to inhibit myogenic differentiation. Cells were transfected with an empty vector (pCS2), full-length GLP (FL-GLP) or a deletion mutant lacking both ANK repeats and SET domain (ΔANKΔSET) (Figure 2A ). Both proteins were expressed at equivalent levels ( Figure 2B ). Overexpression of FL-GLP significantly inhibited myogenic differentiation compared to control cells. However, no significant change in differentiation of ΔANKΔSET cells was seen ( Figure 2C) . Correspondingly, Myogenin and TroponinT levels were lower only in FL-GLP expressing cells ( Figure 2D ). To confirm these findings, GLP was retrovirally overexpressed in C2C12 cells ( Figure 2E ). Compared to control cells, pMaRX-GLP cells showed reduced myogenic differentiation as observed by MHC staining, myogenic index ( Figure 2F ), and downregulation of myogenic markers ( Figure 2G) . No significant change of MyoD levels was seen in undifferentiated pMaRX-GLP cells, while a modest reduction was apparent during differentiation ( Figure 2G ). Altogether, these results confirm that GLP overexpression inhibits myogenesis.
Chromatin organization is altered in GLP-overexpressing cells
Previous studies have shown that GLP interacts with HP1α and HP1γ, and its depletion restricts HP1γ to heterochromatin, suggesting that it may have a role in heterochromatin organization (Tachibana et al., 2005; Chin et al., 2007) . In myoblasts, HP1γ localizes in both euchromatin and heterochromatin but localizes exclusively in heterochromatin upon myogenic differentiation (Agarwal et al., 2007; Sdek et al., 2013) . This association of HP1γ to heterochromatin in myotubes is attributed to MeCP2, which recruits HP1γ to the chromocenters upon the induction of heterochromatin clustering (Agarwal et al., 2007) . We therefore examined whether HP1γ levels or sub-nuclear localization was altered upon GLP overexpression during differentiation. To analyze heterochromatin clustering, cells were differentiated for 6 days when distinctive chromocenter formation is observed (Terranova et al., 2005) . HP1γ levels were unchanged in pMaRX-GLP cells, nor was there any change in H3K9me3, a heterochromatin mark ( Figure 3A) . Focal nuclear staining of heterochromatin can be visualized with DAPI staining of A/T rich satellite repeats. Heterochromatin clustered into distinct chromocenters in both pMaRX and pMaRX-GLP cells ( Figure 3B ). However, pMaRX-GLP cells showed a higher number, but smaller size of DAPI stained chromocenters, and reduced localization of HP1γ to chromocenters compared to control cells ( Figure 3C ), suggesting that heterochromatin clustering may be impaired. H3K9me3 marks are established docking sites for HP1γ, but H3K9me3 sub-nuclear localization was not altered upon GLP overexpression ( Figure 3B and C). To validate these findings, control or siGLP primary myoblasts were differentiated and chromocenters were analyzed. Compared to controls, siGLP cells showed a lower number, larger size of DAPI stained chromocenters, and enhanced HP1γ localization to heterochromatin ( Figure 3D and E).
MeCP2 and HP1γ are redistributed in GLP-overexpressing cells
Since MeCP2 interacts with HP1γ to regulate heterochromatin clustering during myogenic differentiation (Brero et al., 2005;  Figure 3 Chromatin organization during differentiation is altered in GLP-overexpressing cells. (A) pMaRX and pMaRX-GLP cells were differentiated for 0 and 6 days and were analyzed for HP1γ and H3K9me3 levels. β-actin was used as loading control. (B) pMaRX and pMaRX-GLP cells were differentiated for 6 days and immuno-stained with anti-HP1γ (red) and anti-H3K9me3 (green) antibodies. Scale bar, 2 μm. (C) Box and whisker plots show the number of chromocenters per nucleus, average size of chromocenters, Mander's coefficient for HP1γ and DAPI, and Mander's coefficient for H3K9me3 and DAPI in pMaRX and pMaRX-GLP myotubes (from left to right). For each experiment, >50 nuclei were counted in 10-20 random fields. The results are representative of three independent experiments. Error bars indicate the difference between lower quartile and lower extreme and difference between upper quartile and upper extreme, respectively. n.s., P-value not significant. (D) Control and siGLP primary myoblasts were differentiated for 6 days and immuno-stained with anti-HP1γ antibody (red). Scale bar, 2 μm. (E) Box and whisker plots show the number of chromocenters per nucleus, average size of chromocenters, and Mander's coefficient for HP1γ and DAPI in control and siGLP primary myotubes (from left to right). For each experiment, >50 nuclei were counted in 10-20 random fields. The results are representative of two independent experiments. Error bars indicate the difference between lower quartile and lower extreme and difference between upper quartile and upper extreme, respectively. Agarwal et al., 2007) , we examined its expression. Interestingly, MeCP2 expression was decreased in pMaRX-GLP cells compared to control cells ( Figure 4A ). Conversely, its expression was upregulated in siGLP primary myoblasts ( Figure 4B ) suggesting that MeCP2 de-regulation may contribute to modulation of HP1γ localization.
To further ascertain these results, we tested for the presence of HP1γ, MeCP2, and H3K9me3 at heterochromatin by analyzing their occupancy at major satellites in pMaRX-GLP cells. Compared to control cells, pMaRX-GLP cells showed reduced HP1γ and MeCP2 occupancy at major satellites, although H3K9me3 enrichment remained unchanged ( Figure 4C ). Given that MeCP2 binds methylated CG dinucleotides, we tested whether change in DNA methylation at major satellites contributed to reduction of MeCP2 binding at heterochromatin. Combined bisulfite restriction analysis (COBRA) revealed that there was no significant change in DNA methylation at major satellites in pMaRX-GLP cells compared to control cells ( Figure 4D ).
MeCP2 is a GLP target gene
The lower MeCP2 levels in pMaRX-GLP cells suggested that it may be a downstream target of GLP. To test that possibility, we first examined endogenous MeCP2 expression during differentiation. Consistent with previous studies (Brero et al., 2005; Agarwal et al., 2007) , MeCP2 expression dramatically increased upon terminal differentiation and inversely correlated with GLP levels ( Figure 5A ). In pMaRX-GLP cells, MeCP2 transcripts were downregulated suggesting that GLP may transcriptionally repress MeCP2 expression ( Figure 5B ). We also analyzed the expression of another MBD family member MBD2, which has also been shown to induce heterochromatin clustering in skeletal muscle (Brero et al., 2005) . Similar to MeCP2, MBD2 mRNA levels were downregulated in pMaRX-GLP cells ( Figure 5B ). Correspondingly, MeCP2 and MBD2 were upregulated in siGLP primary myoblasts compared to controls ( Figure 5C ). The MeCP2 promoter has been reported to be repressed by H3K9me2 marks (Heard et al., 2001; Abuhatzira et al., 2011) . We therefore examined whether MeCP2 is indeed a GLP target gene by assessing GLP occupancy and H3K9me2 marks at the MeCP2 promoter by ChIP assays. In control cells, GLP occupancy and H3K9me2 marks were higher in undifferentiated cells (Day 0) and reduced during differentiation (Day 3) ( Figure 5D) . A clear enrichment of GLP and H3K9me2 marks were evident at the MeCP2 promoter in pMaRX-GLP cells relative to control in both undifferentiated and differentiated cells ( Figure 5D ). No change in GLP occupancy was seen at the β-actin promoter in pMaRX-GLP cells, which was analyzed as a control ( Figure 5D ).
Since MeCP2 is important for binding and aggregation of pericentric heterochromatin (Brero et al., 2005) , we examined the impact of its depletion during myogenic differentiation. Cells were transfected with scrambled siRNA (Control) or MeCP2-specific siRNA (siMeCP2) ( Figure 6A ). Control and siMeCP2 cells were differentiated and immuno-stained with MeCP2 and HP1γ antibodies. Compared to control cells, siMeCP2 cells had a higher number and smaller size of chromocenters. In addition, similar to GLP-overexpressing cells, HP1γ localization to chromocenters was reduced indicating impaired heterochromatin clustering ( Figure 6B and C) . Given that MeCP2 is a GLP target gene, we investigated whether MeCP2 is downstream of GLP-mediated heterochromatin clustering by expressing exogenous MeCP2 in GLPoverexpressing cells (pMaRX-GLP + MeCP2) ( Figure 6D) . Control, pMaRX-GLP, and pMaRX-GLP + MeCP2 cells were differentiated and heterochromatin clustering was analyzed using anti-MeCP2 and anti-HP1γ antibodies. pMaRX-GLP cells showed a greater number and smaller size of chromocenters, and reduced HP1γ localization compared to controls ( Figure 6E and F) . Expression of exogenous MeCP2 in pMaRX-GLP + MeCP2 cells resulted in similar number and size of chromocenters and HP1γ localization as control cells (Figure 6E and F) .
Endogenous MeCP2 regulates heterochromatin organization and differentiation
Given that exogenous MeCP2 restored heterochromatin clustering in GLP-overexpressing cells, we assessed whether inhibition of heterochromatin clustering by GLP is mediated via repression of endogenous MeCP2. Cells were transfected with scrambled siRNA (Control), siGLP, or both siGLP and siMeCP2 [double knockdown (DKD)]. Consistent with our previous data ( Figure 3D and E), MeCP2 expression was elevated in siGLP cells compared to control cells ( Figure 7A ). We analyzed expression and localization of MeCP2 and HP1γ in differentiated control, siGLP and DKD cells with anti-MeCP2 and anti-HP1γ antibodies. Compared to control cells, siGLP cells showed lower number and larger size of chromocenters as seen by DAPI staining. HP1γ localization to heterochromatin was also increased ( Figure 7B and C) . On the other hand, while DKD cells exhibited no significant change in number of chromocenters compared to control cells ( Figure 7C) , there was a decrease in their size ( Figure 7B ) and HP1γ localization to heterochromatin was reduced ( Figure 7C) . Control, siGLP and DKD cells were also analyzed for myogenic differentiation. Interestingly, the enhanced myogenic differentiation in siGLP cells seen by MHC staining, myogenic index ( Figure 7D) , as well as Myogenin and TroponinT levels ( Figure 7E ), was reversed in DKD cells to a level similar to control cells.
Discussion
Chromatin organization is dynamically altered during myogenic differentiation. However, the mechanisms by which epigenetic alterations lead to distinct domains in chromatin that establish and maintain cell fates is unclear. In this study, we have identified a new role for GLP in transcriptional regulation of MeCP2. This in turn reduces HP1γ recruitment and heterochromatin remodeling during myogenic differentiation.
We demonstrate that GLP inhibits skeletal muscle differentiation. Interestingly, the levels of G9a were unaltered in both siGLP and pMaRX-GLP cells indicating that GLP inhibits muscle differentiation independent of G9a as previously reported (Schaefer et al., 2009; Ohno et al., 2013) . In line with our findings, a recent study also showed inhibition of myogenic differentiation upon GLP overexpression, although it promoted myogenic gene expression in myoblasts due to stabilization of MyoD (Battisti et al., 2016) .
GLP has been reported to interact with HP1γ and DNMT3a (Tachibana et al., 2005; Fritsch et al., 2010; Chang et al., 2011) . However, its overexpression impairs rather than enhances heterochromatin aggregation during differentiation as evidenced by the number and size of DAPI stained chromocenters, as well as reduced HP1γ and MeCP2 localization at pericentric heterochromatin. H3K9me3 levels or DNA methylation at constitutive heterochromatin were not altered upon GLP overexpression. Since MeCP2 recruits HP1γ to heterochromatin during myogenic differentiation (Agarwal et al., 2007) , our data suggests that reduced MeCP2 expression is central to the altered heterochromatin organization upon GLP overexpression. Indeed, knockdown of MeCP2 alone impacts HP1γ localization to heterochromatin mimicking the effect of GLP overexpression. Moreover, MeCP2
Figure 4 GLP alters sub-nuclear distribution of MeCP2 and HP1γ without affecting DNA methylation at major satellites. (A) pMaRX and pMaRX-GLP cells were differentiated for 6 days and immuno-stained with anti-MeCP2 antibody (green). Scale bar, 2 μm. Box and whisker plot shows total corrected cell fluorescence (TCCF) of MeCP2. For each experiment, >50 nuclei were counted in 10-20 random fields. The results are representative of three independent experiments. (B) Control and siGLP primary myoblasts were differentiated for 6 days and immuno-stained with anti-MeCP2 antibody (green). TCCF of MeCP2 in control and siGLP primary myotubes is shown. (C) pMaRX and pMARX-GLP cells were differentiated for 6 days and ChIP assays for occupancy of HP1γ, MeCP2, and H3K9me3 at major satellites were performed. The results are representative of three independent experiments. Bars indicate the mean of Q-PCR triplicates in each experiment ±SD. n.s., P-value not significant. (D) pMaRX and pMARX-GLP cells were differentiated for 6 days and methylation status of major satellite repeat was analyzed. PCR product of bisulfite-treated DNA was digested with (+) or without (−) HpyCH4IV. Methylation percentage was scored. The results are representative of four independent experiments. depletion in GLP-knockdown background reverted the enhanced HP1γ localization to pericentric heterochromatin, as well as myogenic differentiation.
Our findings suggest that the previously established association of GLP with HP1γ (Tachibana et al., 2005; Chin et al., 2007; Fritsch et al., 2010) in euchromatin of undifferentiated myoblasts may be important to transcriptionally repress differentiation genes. Indeed, overexpression of HP1γ has been shown to repress Myogenin expression and curb MyoD transcriptional activity (Yahi et al., 2008) . As GLP levels decline upon differentiation, MeCP2 expression is induced and recruits HP1γ to heterochromatin to repress proliferation genes in terminally differentiating myotubes. Consistent with this model, HP1γ is known to repress cell-cycle genes to maintain postmitotic status of adult cardiac myocytes (Sdek et al., 2011) and cell-cycle genes are preferentially localized to pericentric heterochromatin upon skeletal muscle differentiation (Guasconi et al., 2010) . Thus induction of MeCP2 during myogenic differentiation may be important for stabilization and maintenance of transcriptional programs during maturation of differentiated cells Control, siGLP, and DKD cells were differentiated for 6 days and immunostained with anti-MeCP2 (green) and anti-HP1γ (red) antibodies. Scale bar, 2 μm. (C) Box and whisker plots show the number of chromocenters per nucleus, average size of chromocenters, and Mander's coefficient for HP1γ and DAPI in control, siGLP, and DKD myotubes (from left to right). For each experiment, >50 nuclei were counted in 10-20 random fields. The results are representative of two independent experiments. Error bars indicate the difference between lower quartile and lower extreme and difference between upper quartile and upper extreme, respectively. Significance was calculated using a one-way ANOVA followed by Bonferroni's multiple comparison test. (D) Control, siGLP, and DKD cells were differentiated for 3 days and immuno-stained with anti-MHC antibody (red). Myogenic indices for Control, siGLP, and DKD myotubes were scored. Scale bar, 15 μm. For each experiment, >1000 nuclei in 5 fields were counted and myogenic indices for Control, siGLP, and DKD cells were scored. The results are representative of two independent experiments. Bars indicate the mean of MHC + cells in each experiment ±SD.
Significance was calculated using a one-way ANOVA followed by Bonferroni's multiple comparison test. (E) Control, siGLP, and DKD cells were differentiated for 3 days and expression of Myogenin and TroponinT was analyzed. β-actin was used as loading control. (Brero et al., 2005; Agarwal et al., 2007; Singleton et al., 2011; Becker et al., 2016) . Consistent with previous studies showing that MeCP2 expression is transcriptionally repressed by H3K9me2 (Heard et al., 2001; Abuhatzira et al., 2011) , we demonstrate that GLP represses MeCP2 expression. GLP occupancy and H3K9me2 enrichment is apparent at the MeCP2 promoter in proliferating myoblasts that correlate with inhibition of its expression. The downregulation of GLP during differentiation likely relieves this repression allowing MeCP2 to dramatically increase during myogenic differentiation (Brero et al., 2005; Agarwal et al., 2007) . In line with this notion, in silico MeCP2 promoter analysis revealed that MyoD is able to bind to the MeCP2 promoter, indicating that MyoD could recruit GLP to the MeCP2 promoter and mediate repressive H3K9me2 marks to curb its expression (software Match 1.0, data not shown).
Some studies have shown that MeCP2 does not impact myogenic differentiation likely due to redundancy with MBD2 (Brero et al., 2005; Becker et al., 2013) , and has a non-cell autonomous role in skeletal muscle (Conti et al., 2015) . Nonetheless, elevated MeCP2 expression has a significant detrimental impact on cardiac development in vivo (Alvarez-Saavedra et al., 2010), and peripheral MeCP2 knockout mice, which retain MeCP2 expression in neurons, exhibits reduced exercise capacity and aggravated fatigue (Ross et al., 2016) . Moreover, a recent study using a Rett syndrome zebrafish model with MeCP2 loss-offunction showed severe downregulation of terminal myogenic differentiation genes, such as myosin heavy chain, TroponinT, and muscle-specific creatine kinase, at both embryonic and adult stages (Cortelazzo et al., 2017) . Also, transcriptome analysis in mouse models with MeCP2 loss-of-function and gain-offunction in the hippocampus also indicates that TroponinT is positively regulated by MeCP2 (Chahrour et al., 2008) . Given that depletion of MeCP2 in siGLP cells restored myogenic differentiation to control levels in our study, the difference between our analysis and MeCP2 knockout mice may be attributed to the different models employed in each study. Unlike analysis of terminally differentiated striated skeletal muscle tissue from adult mice, MeCP2 knockdown in myogenic precursor cells in vitro may recapitulate delayed differentiation during development. Analysis of missense Rett syndrome (RTT) mutations that lead to MeCP2 loss-of-function revealed that two-thirds of them show impaired heterochromatin clustering (Agarwal et al., 2011) . It was also recently reported that a scaffolding protein SH2B1 also exerts pro-myogenic effect by modulating heterochromatin clustering during differentiation (Chen et al., 2017) .
Loss-of-function mutations in GLP gene underlie the neurological disorder Kleefstra syndrome (Kleefstra et al., 2006) , whereas gain of MeCP2 leads to MeCP2 duplication syndrome (Amir et al., 1999; Ramocki et al., 2009) . Both Kleefstra syndrome and MeCP2 duplication syndrome exhibit intellectual disability, muscle hypotonia, and dysmorphism as common symptoms. Notably, clinical screening of Kleefstra syndrome patients revealed a de novo missense mutation of MBD5, a methyl-binding protein similar to MeCP2 (Kleefstra et al., 2012 ).
These studies demonstrate genetic interactions between GLP and MeCP2/MBD5. Thus, the GLP-MeCP2 regulatory axis identified in this study may be relevant in both disorders as well as several neuropathologies characterized by loss of MeCP2 expression.
Materials and methods
Cell culture and differentiation assays C2C12 cells were cultured in high glucose Dulbecco's Modified Eagle's Medium (DMEM; Sigma) supplemented with 20% fetal bovine serum (FBS; Hyclone). To induce differentiation, cells were cultured to 80%-90% confluency in growth media, and then cultured in differentiation medium [DMEM with 2% horse serum (Invitrogen)]. HEK293T and Phoenix cell lines were cultured in DMEM supplemented with 10% FBS. Isolation of primary myoblasts has been previously described (Sun et al., 2007; Rao et al., 2016) . Differentiation was assessed by MHC staining as previously described (Ling et al., 2012) . Briefly, differentiated cells were stained with mouse monoclonal anti-MHC (Sigma) antibody, and detected with secondary antibody conjugated to Alexa Fluor (Alexa Fluor 488; 568; Invitrogen). Nuclei were stained with the fluorochrome 4′,6-diamino-2-phenylindole (DAPI). Images were captured under Olympus DP72 fluorescence microscope. More than 1000 nuclei from five different fields were counted. Myogenic index was calculated by quantifying the ratio of nuclei in myosin heavy chain-positive myotubes to total nuclei.
Plasmids, retroviral infection, and siRNA
Plasmids FLAG-GLP and FLAG-ΔANKΔSET that lacks ANK repeats and SET domain of GLP have been previously described (Takahashi et al., 2012) . To generate stable cell lines, C2C12 cells were transfected with FLAG-GLP or FLAG-ΔANKΔSET and pBABE vector in a 9:1 ratio using Lipofectamine 2000 reagent (Invitrogen). Mouse MeCP2 plasmid was purchased from ORIGENE (MR226839). Cells were selected with puromycin for 48 h and analyzed in differentiation experiments. Alternatively, pMaRX or pMaRX-GLP retroviral constructs were transfected into Phoenix packaging cells. Retroviral supernatants were used to transduce undifferentiated C2C12 cells with 8 μg/ml polybrene. Cells were subsequently subjected to selection with medium containing 2 μg/ml of puromycin for 48 h. Knockdown experiments were performed using 50 nM GLP-specific siRNA (siGLP; ONTARGETplusSMARTpool; NM_001012518) or 50 nM MeCP2-specific siRNA (siMeCP2; ON-TARGETplusSMARTpool; NM_001081979) from Dharmacon using Lipofectamine RNAiMAX (Invitrogen) as described in the manufacturer's protocol. Control cells were transfected with non-specific scrambled siRNA (Dharmacon, ONTARGETplus, Non-Targeting Pool). Transfection of siRNA was done in growth medium for 48 h.
RNA isolation and quantitative real-time polymerase chain reaction (Q-PCR)
Total RNA was extracted using Trizol (Invitrogen). RNA was quantified using Nanodrop. Messenger RNA (mRNA) was converted to a single-stranded complementary DNA (cDNA) using iScript cDNA Synthesis Kit (Bio-Rad). Quantitative realtime polymerase chain reaction (Q-PCR) was performed using Lightcycler 480 SYBR Green 1 Master Kit (Roche). CT values of samples were normalized to internal control Gapdh to obtain delta CT (ΔCT). Relative expression was calculated by 2 −ΔCT equation. Primer sequences for GLP (Ohno et al., 2013) , Myogenin (Ling et al., 2012) , MeCP2 (Murgatroyd et al., 2009) , and MBD2 (Song et al., 2014) have been previously described. For Myh1, the following set of primers were used: 5′-AACAGCAGCGGCTGATCAAT-3′ and 5′-GCTGCCTCTTCAGCTCCTCA-3′.
Chromatin immuno-precipitation (ChIP)
ChIP assays were done as previously described (Ling et al., 2012) . Briefly, 1 × 10 6 cells were cross-linked with 1% formaldehyde for 10 min at 37°C. Cells were sonicated using Bioruptor (Diagenode). ChIP was carried out according to the kit protocol (Millipore). Immuno-precipitates were reverse-cross-linked and DNA was extracted using phenol-chloroform-isoamylalcohol (Sigma). Q-PCR was performed as described above. DNA harvested from 10% input was used as control. Relative enrichment was calculated using 2 −ΔCT equation. Following antibodies were used for ChIP assays: mouse monoclonal ChIP-grade anti-GLP (Abcam, ab41969), anti-H3K9me2 (Millipore, 17-681), anti-HP1γ (Millipore, MAB3450), anti-MeCP2 (Abcam, ab07013), antiH3K9me3 (Abcam ab8898). Primers used for ChIP assays of MeCP2 promoters (Heard et al., 2001) , major satellites (Terranova et al., 2005) , and β-actin have been described previously.
Cell proliferation assay Proliferation was measured using BrdU incorporation assays (Azmi et al., 2004) . Cells were pulsed with 10 μM BrdU for 30 min. Cells were fixed and stained with anti-BrdU antibody according to manufacturer's protocol (Roche). More than 1000 nuclei from five different fields were counted. BrdU positivity was calculated.
Immunofluorescence imaging and analysis
For confocal imaging, samples were permeabilized with 0.1% Triton X-100 for 1 h at room temperature and blocked overnight in 10% horse serum in PBS. Samples were probed with primary antibodies overnight at 4°C in blocking buffer with 0.1 M glycine (Brocher et al., 2010) . Primary antibodies used for immunofluorescence are anti-MeCP2 (Cell Signaling, 1:200), anti-HP1γ (Millipore, MAB3450, 1:350), and anti-H3K9me3 (Abcam, ab8988, 1:1000). Images were captured under FluoView FV1000 confocal fluorescence microscope (Olympus) with optical section thickness 1μm. More than 50 nuclei for each sample were counted for three independent experiments, unless otherwise stated. Number and size of DAPI positive chromocenters were quantified using 'cell counter' and 'analyze particle' tools in ImageJ software as described previously (Novo et al., 2016) . Mander's coefficient was used to measure the co-localization of DAPI and HP1γ using 'JACoP' tool in ImageJ as described previously (Bolte and Cordelières, 2006) . Expression of MeCP2 was quantified using the total corrected cellular fluorescence (TCCF) equation as described previously (McCloy et al., 2014) . Box and whisker plots were plotted using Microsoft Excel software.
Combined bisulfite restriction assay (COBRA)
COBRA assay was performed as previously described (Xiong and Laird, 1997) . Briefly, genomic DNA (gDNA) was extracted using GeneJET Genomic DNA purification Kit (Thermo Fisher Scientific). gDNA was subject to bisulfite treatment using EZ DNA Methylation-Gold Kit (Zymo Research). Eluted DNA was PCR-amplified using the following set of primers: 5′-GGAATATGG CAAGAAAACTGAAAATCATGG-3′ and 5′-CCATATTCCAGGTCCTTCA GTGTGCATTTC-3′. The PCR reaction was carried out for 35 cycles of 95°C for 30 sec, 58°C for 60 sec, and 68°C for 20 sec. The purified PCR products were digested with restriction enzyme HpyCH4IV, which has a recognition sequence (ACGT) that should be destroyed by the bisulfite conversion. Restriction digestion reactions were performed at 37°C for 30 min. The digested PCR products were separated on 1% polyacrylamide gel and were visualized with ChemiDoc imaging system (Bio-rad). DNA methylation was calculated by quantifying ratio of methylated DNA and sum of un-and methylated DNA.
Immunoblotting
Protein lysate was harvested in radioimmunoprecipitation assay (RIPA) lysis buffer [50 mM NaCl, 50 mM Tris-HCl pH 7.0, 1 mM EDTA, 1% NP-40, 0.1% sodium deoxycholate, protease inhibitor cocktail (Roche)]. Histones were isolated using RIPA lysis buffer supplemented with 2% sodium dodecyl sulfate (SDS). The following primary antibodies were used for immunoblotting: mouse monoclonal anti-GLP (Abcam, ab41969, 1:2000) , rabbit polyclonal anti-Myogenin (Santa Cruz Biotechnology, sc-576, 1:500), mouse monoclonal anti-Troponin-T (Sigma, T6277, 1:2000), rabbit polyclonal anti-MyoD (Santa Cruz Biotechnology, sc-304, 1:500), mouse monoclonal anti-Flag (Sigma, F3165, 1:500), rabbit polyclonal anti-MeCP2 (Cell Signaling, 3456, 1:2000) , anti-HP1γ (Millipore, MAB3450, 1:5000), anti-H3K9me3 (Abcam, ab8988, 1:2000) , and mouse monoclonal anti-β-actin (Sigma, A1978, 1:10000).
Statistical analysis
Significance was calculated using student's t test (two-sided) and P values <0.05 were considered to be statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001). Bars represent mean ± standard deviation (SD) unless specified otherwise. For quantification significance for data with more than two groups, a one-way ANOVA followed by Bonferroni's multiple comparison test was performed and P values <0.05 were considered to be statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001).
image analysis, and Dr Neerja Karnani (National University of Singapore) for valuable discussions.
